This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, C. Articles by Alman, B. A. Search for Related Content PubMed PubMed Citation Articles by Wu, C. Articles by Alman, B. A.

Side Population Cells Isolated from Mesenchymal Neoplasms Have Tumor Initiating Potential

¹ Program in Developmental and Stem Cell Biology and ² Department of Surgery, Hospital for Sick Children; and ³ Department of Laboratory Medicine and Pathology and ⁴ Department of Surgery, Mount Sinai Hospital, University of Toronto, Ontario, Canada

Requests for reprints: Benjamin A. Alman, Program in Developmental and Stem Cell Biology, Toronto Medical Discovery Tower, East Tower, 101 College Street, Toronto, ON, Canada M5G 1L7. Phone: 416-813-2178; Fax: 416-813-2617; E-mail: benjamin.alman{at}sickkids.ca.

Although many cancers are maintained by tumor-initiating cells, this has not been shown for mesenchymal tumors, in part due to the lack of unique surface markers that identify mesenchymal progenitors. An alternative technique to isolate stem-like cells is to isolate side population (SP) cells based on efflux of Hoechst 33342 dye. We examined 29 mesenchymal tumors ranging from benign to high-grade sarcomas and identified SP cells in all but six samples. There was a positive correlation between the percentage of SP cells and the grade of the tumor. SP cells preferentially formed tumors when grafted into immunodeficient mice, and only cells from tumors that developed from the SP cells had the ability to initiate tumor formation upon serial transplantation. Although SP cells are able to efflux rhodamine dye in addition to Hoechst 33342, we found that the ability to efflux rhodamine dye did not identify a population of cells enriched for tumor-initiating capacity. Here, we identify a subpopulation of cells within a broad range of benign and malignant mesenchymal tumors with tumor-initiating capacity. In addition, our data suggest that the proportion of SP cells could be used as a prognostic factor and that therapeutically targeting this subpopulation of cells could be used to improve patient outcome. [Cancer Res 2007;67(17):8216–22]

This article has been cited by other articles:

				J. M. Lubieniecka, D. R.H. de Bruijn, L. Su, A. H.A. van Dijk, S. Subramanian, M. van de Rijn, N. Poulin, A. G. van Kessel, and T. O. Nielsen Histone Deacetylase Inhibitors Reverse SS18-SSX-Mediated Polycomb Silencing of the Tumor Suppressor Early Growth Response 1 in Synovial Sarcoma Cancer Res., June 1, 2008; 68(11): 4303 - 4310. [Abstract] [Full Text] [PDF]

				S. L. Spunt, S. X. Skapek, and C. M. Coffin Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcomas Oncologist, June 1, 2008; 13(6): 668 - 678. [Abstract] [Full Text] [PDF]